Core Viewpoint - ST Bailin (002424.SZ) has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which enhances the company's intellectual property protection and competitive edge [1] Group 1: Patent Application Details - The accepted patent application is for a traditional Chinese medicine formulation for treating diabetes or its complications, based on years of research from the company's Tang Ning Tong Luo project [1] - The confidentiality of the patent application covers the formulation composition, production process, and multiple treatment areas, with a protection period aligned with the "secret" confidentiality period under the National Confidentiality Law of the People's Republic of China [1] Group 2: Implications for the Company - The acceptance of this confidential patent will provide comprehensive and tighter core intellectual property protection for the Tang Ning Tong Luo project [1] - If the patent is ultimately granted, it will help the company avoid core technology leakage and accelerate clinical promotion and market conversion, thereby enhancing the company's core competitiveness [1]

Core Viewpoint - The company has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which could enhance intellectual property protection for its ongoing project if granted [1] Group 1 - The patent application number is 202610042695.2, and the invention is based on the company's long-term research in the "Tian Ning Tong Luo" project [1] - The acceptance of the patent application is currently in the review stage, which carries the risk of not passing the examination and being granted [1] - The current status of the patent application will not have a significant impact on the company's operations [1]